Antioxidant vitamins E and C and risk of Alzheimer's disease

Nutrition Reviews

Volumn 61, Issue 2, 2003, Pages 69-73

  Martin, Antonio ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Aging; Alzheimer's disease; Antioxidant; Neurocognition

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID;

AGING; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; COGNITION; DEGENERATIVE DISEASE; DEMENTIA; DISEASE PREDISPOSITION; HUMAN; SHORT SURVEY; AGED; FEMALE; MALE; MIDDLE AGED; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR;

AGED; AGING; ALZHEIMER DISEASE; ANTIOXIDANTS; ASCORBIC ACID; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; VITAMIN E;

EID: 0038006958     PISSN: 00296643     EISSN: None     Source Type: Journal    
DOI: 10.1301/nr.2003.febr.69-73     Document Type: Short Survey

References (40)

1. Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology. 2002;58:1629-1634.
2. Bowler JV, Wade JP, Jones BE, Nijran KS, Steiner TJ. Natural history of the spontaneous reperfusion of human cerebral infarcts as assessed by 99mTc HMPAO SPECT. J Neurol Neurosurg Psychiatry. 1998;64:90-97.
3. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337-1342.
4. Seshadri S, Wolf PA, Beiser A, et al. Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham Study. Neurology. 1997;49:1498-1504.
5. Souder E, Chastain JR, Williams RD. Dementia in the new millennium. Medsurg Nurs. 2002;11:61-69, 70.
6. Koppel R. Alzheimer's disease: the costs to U.S. businesses in 2002. Prepared for the Alzheimer's Association. Philadelphia, PA: Social Research Corporation and Department of Sociology, University of Pennsylvania; 2002:1-28.
7. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health. 1994;84:1261-1264.
8. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med. 1997;23:134-147.
9. Andorn AC, Pappolla MA. Catecholamines inhibit lipid peroxidation in young, aged, and Alzheimer's disease brain. Free Radic Biol Med. 2001;31:315-320.
10. Behl C. Amyloid beta-protein toxicity and oxidative stress in Alzheimer's disease. Cell Tissue Res. 1997; 290:471-480.
11. Butterfield DA, Yatin SM, Varadarajan S, Koppal T. Amyloid beta-peptide-associated free radical oxidative stress, neurotoxicity, and Alzheimer's disease. Methods Enzymol. 1999;309:746-768.
12. Monji A, Utsumi H, Ueda T, et al. The relationship between the aggregational state of the amyloid-beta peptides and free radical generation by the peptides. J Neurochem. 2001;77:1425-1432.
13. Behl C, Holsboer F. Oxidative stress in the pathogenesis of Alzheimer's disease and antioxidant neuroprotection. Fortschr Neurol Psychiatr. 1998;66:113-121.
14. Feillet-Coudray C, Tourtauchaux R, Niculescu M, et al. Plasma levels of 8-epiPGF2alpha, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease. Free Radic Biol Med. 1999; 27:463-469.
15. Hauss-Wegrzyniak B, Lynch MA, Vraniak PD, Wenk GL. Chronic brain inflammation results in cell loss in the entorhinal cortex and impaired LTP in perforant path-granule cell synapses. Exp Neurol. 2002;176:336-341.
16. Grant WB, Campbell A, Itzhaki RF, Savory J. The significance of environmental factors in the etiology of Alzheimer's disease. J Alzheimers Dis. 2002;4:179-189.
17. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol. 2002;52:168-174.
18. Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci. 2000;20:5709-5714.
19. Emilien G, Beyreuther K, Masters CL, Maloteaux JM. Prospects for pharmacological intervention in Alzheimer disease. Arch Neurol. 2000;57:454-459.
20. Gemma C, Mesches MH, Sepesi B, Choo K, Holmes DB, Bickford PC. Diets enriched in foods with high antioxidant activity reverse age-induced decreases in cerebellar beta-adrenergic function and increases in proinflammatory cytokines. J Neurosci. 2002;22:6114-6120.
21. Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA. 2002;287:3223-3229.
22. Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology. 2002;59:880-886.
23. Helmuth L. NSAIDS for prevention? Protecting the brain while killing pain? Science. 2002;297:1262-1263.
24. Aisen PS. Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. J Pain Symptom Manage. 2002;23:S35-S40.
25. Abate A, Yang G, Dennery PA, Oberle S, Schroder H. Synergistic inhibition of cyclooxygenase-2 expression by vitamin E and aspirin. Free Radic Biol Med. 2000;29:1135-1142.
26. Vatassery GT. Vitamin E and other endogenous antioxidants in the central nervous system. Geriatrics. 1998;53:S25-S7.
27. Li Y, Liu L, Barger SW, Mrak RE, Griffin WS. Vitamin E suppression of microglial activation is neuroprotective. J Neurosci Res. 2001;66:163-170.
28. Brigelius-Flohe R, Kelly FJ, Salonen JT, Neuzil J, Zingg JM, Azzi A. The European perspective on vitamin E: current knowledge and future research. Am J Clin Nutr. 2002;76:703-716.
29. Devaraj S, Li D, Jialal I. The effects of alpha tocopherol supplementation on monocyte function. Decreased lipid oxidation, interleukin 1 beta secretion, and monocyte adhesion to endothelium. J Clin Invest. 1996;98:756-763.
30. Ricciarelli R, Tasinato A, Clement S, Ozer NK, Boscoboinik D, Azzi A. α-Tocopherol specifically inactivates cellular protein kinase C alpha by changing its phosphorylation state. Biochem J. 1998;334:243-249.
31. Diliberto EJ Jr, Dean G, Carter C, Allen PL. Tissue, subcellular, and submitochondrial distributions of semidehydroascorbate reductase: possible role of semidehydroascorbate reductase in cofactor regeneration. J Neurochem. 1982;39:563-568.
32. Launer LJ. Is there epidemiologic evidence that anti-oxidants protect against disorders in cognitive function? J Nutr Health Aging. 2000;4:197-201.
33. Morris MC, Beckett LA, Scherr PA, et al. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord. 1998;12:121-126.
34. Masaki KH, Losonczy KG, Izmirlian G, et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology. 2000;54:1265-1272.
35. Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS. Vitamin E and cognitive decline in older persons. Arch Neurol. 2002;59:1125-1132.
36. Morris MC, Evans DA, Bienias JL, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA. 2002;287:3230-3237.
37. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997;336:1216-1222.
38. Bender MM, Levy AS, Schucker RE, Yetley EA. Trends in prevalence and magnitude of vitamin and mineral supplement usage and correlation with health status. J Am Diet Assoc. 1992;92:1096-1101.
39. Kirk SF, Cade JE, Barrett JH, Conner M. Diet and lifestyle characteristics associated with dietary supplement use in women. Public Health Nutr. 1999;2:69-73.
40. Ritchie K, Dupuy AM. The current status of apo E4 as a risk factor for Alzheimer's disease: an epidemiological perspective. Int J Geriatr Psychiatry. 1999;14:695-700.